Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose basiliximab plus corticosteroids in steroid-refractory ulcerative colitis
2006-004303-19Phase 2Completed
- Sponsor
- Cerimon Pharmaceuticals, Inc.
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Basiliximab + corticosteroids with Placebo + corticosteroids (2 arms). Primary endpoint: Clinical remission at week 8. Started Dec 2006; status: completed.
02
Drugs
basiliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-004303-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004303-19.